Compare · CAI vs ILMN
CAI vs ILMN
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $19.43B, about 20.0x CAI ($971.9M).
- Over the past year, CAI is down 27.6% and ILMN is up 65.7% - ILMN leads by 93.3 points.
- CAI has been more active in the news (10 items in the past 4 weeks vs 5 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 14 for CAI).
- Company
- Caris Life Sciences Inc.
- Illumina Inc.
- Price
- $20.21+2.12%
- $127.93+2.01%
- Market cap
- $971.9M
- $19.43B
- 1M return
- +8.92%
- +1.37%
- 1Y return
- -27.61%
- +65.69%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 10
- 5
- Recent ratings
- 14
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CAI
- Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form DEFA14A filed by Caris Life Sciences Inc.
- SEC Form DEF 14A filed by Caris Life Sciences Inc.
- Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026
- Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center
- Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
- Jefferies initiated coverage on Caris Life Sciences with a new price target
- Piper Sandler initiated coverage on Caris Life Sciences with a new price target
- Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
- Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.
Latest ILMN
- DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
- Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
- Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
- SEC Form DEFA14A filed by Illumina Inc.
- SEC Form DEF 14A filed by Illumina Inc.
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Meister Keith A.
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Illumina Announces Changes to Board of Directors
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.